Allergic Reactions
We recommend
Bilastine and its role in the treatment of allergic rhinoconjunctivitis and urticaria in children
The prevalence of allergic rhinitis (AR) in the pediatric population is estimated worldwide at 10-20%. The efficacy and safety of bilastine (a second-generation antihistamine) in adult patients and adolescents have already been proven in clinical studies. Below we summarize experiences with its use in children under 12 years of age.
Indication of Bilastine in Specific Patient Groups − Practical Tips for Clinical Practice
Bilastine is a non-sedating H1-antihistamine, which is very well tolerated by patients. It can be…
Bilastine in the treatment of allergic rhinitis – meta-analysis shows advantage of lower somnolence
A newly published systematic review and meta-analysis evaluate the efficacy and safety of bilastine…
Articles on this topic
Nasal Smear as a Modern and Gentle Diagnostic Method for Allergic Rhinitis
Up to 130 million Europeans suffer from allergic rhinitis. Until now, standard diagnostic…
Impact of Chronic Urticaria on Patients' Quality of Life and Society
An international team of dermatologists has mapped out the impact of chronic urticaria on…
Bilastine as a reliable helper in the treatment of allergic rhinoconjunctivitis and urticaria even in younger children
Until recently, bilastine was indicated for the treatment of allergic rhinoconjunctivitis and…
Dynamics of Allergy Development in Children
The prevalence of allergic diseases in children in developed countries has been steadily…
Use of Bilastine in Pediatrics − Pathway to Improving Concentration and Performance of Young Allergy Sufferers
In the treatment of allergic diseases, especially in children, safety, good tolerability,…
Pharmacokinetics and Safety of Bilastine 10 mg in Children Aged 6–11 Years
The second-generation antihistamine bilastine is approved in Europe for the treatment of…
Safety and Tolerability of Bilastine in the Treatment of Chronic Urticaria in Children
Chronic urticaria is less common in pediatric patients compared to the acute form, but it…
Incidence of Allergic Diseases in Children Probably Unrelated to Air Pollution
A recently published extensive meta-analysis of 7 cohorts of children aged 4 and 8 from 5…
Pharmacokinetics and Safety Profile of Bilastine in Patients Aged 6–11 Years – Findings from Post-hoc Analysis of Studies
The second-generation antihistamine bilastine is approved in Europe for the treatment of…
Subscribe
Most read on this topic
Journal on this topic
Related topic
Most read on this topic
- Nasal Smear as a Modern and Gentle Diagnostic Method for Allergic Rhinitis
- Bilastine and its role in the treatment of allergic rhinoconjunctivitis and urticaria in children
- Use of Bilastine in Pediatrics − Pathway to Improving Concentration and Performance of Young Allergy Sufferers
- Dynamics of Allergy Development in Children
- Safety and Tolerability of Bilastine in the Treatment of Chronic Urticaria in Children
- Bilastine as a reliable helper in the treatment of allergic rhinoconjunctivitis and urticaria even in younger children
Journal on this topic
Related topic